Glioblastoma Market Research Report - Forecast till 2030

Glioblastoma Market: Information by Type (Primary Glioblastoma and Secondary Glioblastoma), by Treatment (Surgical Procedure, Radiation Therapy, Chemotherapy and others), by End User (Hospitals, Specialty Clinics & Centers and others) and by Region (Americas, Europe, Asia-Pacific and the Middle East & Africa) - Forecast till 2030

ID: MRFR/HC/6835-CR | September 2019 | Region: Global | 133 Pages         

1 EXECUTIVE SUMMARY

1.1 MARKET SYNOPSIS 13

1.2 KEY CONTRIBUTING FACTORS 14

1.3 MARKET ATTRACTIVENESS ANALYSIS 15

1.4 GLOBAL GLIOBLASTOMA MARKET, BY TYPE 16

1.5 GLOBAL GLIOBLASTOMA MARKET, BY TREATMENT 17

1.6 GLOBAL GLIOBLASTOMA MARKET, BY END USER 18

2 MARKET INTRODUCTION

2.1 DEFINITION 19

2.2 SCOPE OF THE STUDY 19

2.3 RESEARCH OBJECTIVE 19

2.4 MARKET STRUCTURE 20

2.5 ASSUMPTIONS & LIMITATIONS 20

3 RESEARCH METHODOLOGY

3.1 DATA MINING 21

3.2 SECONDARY RESEARCH 22

3.3 PRIMARY RESEARCH 23

3.4 BREAKDOWN OF PRIMARY RESPONDENTS 24

3.5 FORECASTING TECHNIQUES 25

3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 26

3.6.1 BOTTOM-UP APPROACH 27

3.6.2 TOP-DOWN APPROACH 27

3.7 DATA TRIANGULATION 28

3.8 VALIDATION 28

4 MARKET DYNAMICS

4.1 OVERVIEW 29

4.2 DRIVERS 30

4.2.1 INCREASING INCIDENCE RATE OF GLIOBLASTOMA AND BRAIN CANCER 30

4.2.2 INCREASING RESEARCH ON GLIOBLASTOMA AND BRAIN TUMORS 30

4.2.3 RISING ADOPTION OF CHEMOTHERAPY 30

4.2.4 INCREASING GERIATRIC POPULATION 30

4.2.5 RISING PER CAPITA HEALTHCARE EXPENDITURE 31

4.3 RESTRAINTS 32

4.3.1 TERMINATION OF CLINICAL TRIALS 32

4.3.2 HIGH COST OF DRUGS 32

4.4 OPPORTUNITIES 33

4.4.1 UPCOMING APPROACHES FOR THE TREATMENT OF GLIOBLASTOMA 33

4.4.2 EXPANSION IN UNTAPPED REGIONS 33

5 MARKET FACTOR ANALYSIS

5.1 PORTER’S FIVE FORCES MODEL 34

5.1.1 BARGAINING POWER OF SUPPLIERS 35

5.1.2 BARGAINING POWER OF BUYERS 35

5.1.3 THREAT OF NEW ENTRANTS 35

5.1.4 THREAT OF SUBSTITUTES 35

5.1.5 INTENSITY OF RIVALRY 35

5.2 VALUE CHAIN ANALYSIS 36

5.2.1 R&D AND DESIGNING 37

5.2.2 MANUFACTURING 37

5.2.3 DISTRIBUTION 37

5.2.4 MARKETING & SALES 37

5.2.5 POST-SALES MONITORING 37

5.3 CLINICAL TRIAL ANALYSIS 38

5.3.1 OVERVIEW 38

5.3.2 TERMINATED CLINICAL TRIALS 39

6 GLOBAL GLIOBLASTOMA MARKET BY TYPE

6.1 OVERVIEW 40

6.2 PRIMARY GLIOBLASTOMA 41

6.3 SECONDARY GLIOBLASTOMA 42

7 GLOBAL GLIOBLASTOMA MARKET BY TREATMENT

7.1 OVERVIEW 43

7.2 SURGICAL PROCEDURE 44

7.3 RADIATION THERAPY 45

7.4 CHEMOTHERAPY 46

7.5 OTHERS 46

8 GLOBAL GLIOBLASTOMA MARKET BY END USER

8.1 OVERVIEW 47

8.2 HOSPITALS 48

8.3 SPECIALTY CLINICS & CENTERS 49

8.4 OTHERS 49

9 GLOBAL GLIOBLASTOMA MARKET BY REGION

9.1 OVERVIEW 50

9.2 AMERICAS 52

9.2.1 NORTH AMERICA 55

9.2.1.1 US 57

9.2.1.2 CANADA 58

9.2.2 LATIN AMERICA 59

9.3 EUROPE 61

9.3.1 WESTERN EUROPE 63

9.3.1.1 GERMANY 66

9.3.1.2 FRANCE 67

9.3.1.3 UK 68

9.3.1.4 ITALY 70

9.3.1.5 SPAIN 71

9.3.1.6 REST OF WESTERN EUROPE 72

9.3.2 EASTERN EUROPE 74

9.4 ASIA-PACIFIC 76

9.4.1 JAPAN 79

9.4.2 CHINA 80

9.4.3 AUSTRALIA 81

9.4.4 INDIA 83

9.4.5 SOUTH KOREA 84

9.4.6 REST OF ASIA-PACIFIC 85

9.5 MIDDLE EAST & AFRICA 87

9.5.1 MIDDLE EAST 89

9.5.2 AFRICA 91

10 COMPETITIVE LANDSCAPE

10.1 OVERVIEW 93

10.2 COMPANY SHARE ANALYSIS 93

10.3 KEY DEVELOPMENTS 94

10.3.1 NEW PRODUCT LAUNCH/APPROVAL 94

10.3.2 MERGERS & ACQUISITIONS 95

10.3.3 PRODUCT DEVELOPMENT 96

11 COMPANY PROFILE

11.1 F. HOFFMANN-LA ROCHE LTD 97

11.1.1 COMPANY OVERVIEW 97

11.1.2 FINANCIAL OVERVIEW 98

11.1.3 PRODUCTS/SERVICES OFFERED 99

11.1.4 KEY DEVELOPMENTS 99

11.1.5 SWOT ANALYSIS 100

11.1.6 KEY STRATEGIES 100

11.2 ARBOR PHARMACEUTICALS, LLC 101

11.2.1 COMPANY OVERVIEW 101

11.2.2 FINANCIAL OVERVIEW 101

11.2.3 PRODUCTS/SERVICES OFFERED 101

11.2.4 KEY DEVELOPMENTS 101

11.2.5 SWOT ANALYSIS 102

11.2.6 KEY STRATEGIES 102

11.3 MERCK & CO., INC. 103

11.3.1 COMPANY OVERVIEW 103

11.3.2 FINANCIAL OVERVIEW 103

11.3.3 PRODUCTS/SERVICES OFFERED 104

11.3.4 KEY DEVELOPMENTS 104

11.3.5 SWOT ANALYSIS 105

11.3.6 KEY STRATEGIES 105

11.4 TEVA PHARMACEUTICAL INDUSTRIES LTD 106

11.4.1 COMPANY OVERVIEW 106

11.4.2 FINANCIAL OVERVIEW 106

11.4.3 PRODUCTS/SERVICES OFFERED 107

11.4.4 KEY DEVELOPMENTS 107

11.4.5 SWOT ANALYSIS 107

11.4.6 KEY STRATEGIES 108

11.5 SUN PHARMACEUTICAL INDUSTRIES LTD 109

11.5.1 COMPANY OVERVIEW 109

11.5.2 FINANCIAL OVERVIEW 110

11.5.3 PRODUCTS/SERVICES OFFERED 111

11.5.4 KEY DEVELOPMENTS 111

11.5.5 SWOT ANALYSIS 112

11.5.6 KEY STRATEGIES 112

11.6 AMGEN INC. 113

11.6.1 COMPANY OVERVIEW 113

11.6.2 FINANCIAL OVERVIEW 113

11.6.3 PRODUCTS/SERVICES OFFERED 114

11.6.4 KEY DEVELOPMENTS 114

11.6.5 SWOT ANALYSIS 115

11.6.6 KEY STRATEGIES 115

12 APPENDIX

12.1 REFERENCES 116

12.2 RELATED REPORTS 116

13 LIST OF TABLES

TABLE 1 LIST OF ASSUMPTIONS 20

TABLE 2 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS 24

TABLE 3 GLIOBLASTOMA: ONGOING CLINICAL TRIALS 38

TABLE 4 TERMINATED CLINICAL TRIALS FOR GLIOBLASTOMA 39

TABLE 5 GLOBAL GLIOBLASTOMA MARKET, BY TYPE, 2020–2027 (USD MILLION) 41

TABLE 6 GLOBAL GLIOBLASTOMA MARKET FOR PRIMARY GLIOBLASTOMA, BY REGION, 2020–2027 (USD MILLION) 41

TABLE 7 GLOBAL GLIOBLASTOMA MARKET FOR SECONDARY GLIOBLASTOMA, BY REGION, 2020–2027 (USD MILLION) 42

TABLE 8 GLOBAL GLIOBLASTOMA MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 44

TABLE 9 GLOBAL GLIOBLASTOMA MARKET FOR SURGICAL PROCEDURE, BY REGION, 2020–2027 (USD MILLION) 44

TABLE 10 GLOBAL GLIOBLASTOMA MARKET FOR RADIATION THERAPY, BY REGION, 2020–2027 (USD MILLION) 45

TABLE 11 GLOBAL GLIOBLASTOMA MARKET FOR CHEMOTHERAPY, BY REGION, 2020–2027 (USD MILLION) 46

TABLE 12 GLOBAL GLIOBLASTOMA MARKET, BY END USER, 2020–2027 (USD MILLION) 48

TABLE 13 GLOBAL GLIOBLASTOMA MARKET FOR HOSPITALS, BY REGION, 2020–2027 (USD MILLION) 48

TABLE 14 GLOBAL GLIOBLASTOMA MARKET FOR SPECIALTY CLINICS & CENTERS, BY REGION, 2020–2027 (USD MILLION) 49

TABLE 15 GLOBAL GLIOBLASTOMA MARKET, BY REGION, 2020–2027 (USD MILLION) 51

TABLE 16 AMERICAS: GLIOBLASTOMA MARKET, BY REGION, 2020–2027 (USD MILLION) 53

TABLE 17 AMERICAS: GLIOBLASTOMA MARKET, BY TYPE, 2020–2027 (USD MILLION) 53

TABLE 18 AMERICAS: GLIOBLASTOMA MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 54

TABLE 19 AMERICAS: GLIOBLASTOMA MARKET, BY END USER, 2020–2027 (USD MILLION) 54

TABLE 20 NORTH AMERICA: GLIOBLASTOMA MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 55

TABLE 21 NORTH AMERICA: GLIOBLASTOMA MARKET, BY TYPE, 2020–2027 (USD MILLION) 56

TABLE 22 NORTH AMERICA: GLIOBLASTOMA MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 56

TABLE 23 NORTH AMERICA: GLIOBLASTOMA MARKET, BY END USER, 2020–2027 (USD MILLION) 56

TABLE 24 US: GLIOBLASTOMA MARKET, BY TYPE, 2020–2027 (USD MILLION) 57

TABLE 25 US: GLIOBLASTOMA MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 57

TABLE 26 US: GLIOBLASTOMA MARKET, BY END USER, 2020–2027 (USD MILLION) 58

TABLE 27 CANADA: GLIOBLASTOMA MARKET, BY TYPE, 2020–2027 (USD MILLION) 58

TABLE 28 CANADA: GLIOBLASTOMA MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 58

TABLE 29 CANADA: GLIOBLASTOMA MARKET, BY END USER, 2020–2027 (USD MILLION) 59

TABLE 30 LATIN AMERICA: GLIOBLASTOMA MARKET, BY TYPE, 2020–2027 (USD MILLION) 59

TABLE 31 LATIN AMERICA: GLIOBLASTOMA MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 60

TABLE 32 LATIN AMERICA: GLIOBLASTOMA MARKET, BY END USER, 2020–2027 (USD MILLION) 60

TABLE 33 EUROPE: GLIOBLASTOMA MARKET, BY REGION, 2020–2027 (USD MILLION) 62

TABLE 34 EUROPE: GLIOBLASTOMA MARKET, BY TYPE, 2020–2027 (USD MILLION) 62

TABLE 35 EUROPE: GLIOBLASTOMA MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 62

TABLE 36 EUROPE: GLIOBLASTOMA MARKET, BY END USER, 2020–2027 (USD MILLION) 63

TABLE 37 WESTERN EUROPE: GLIOBLASTOMA MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 64

TABLE 38 WESTERN EUROPE: GLIOBLASTOMA MARKET, BY TYPE, 2020–2027 (USD MILLION) 64

TABLE 39 WESTERN EUROPE: GLIOBLASTOMA MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 65

TABLE 40 WESTERN EUROPE: GLIOBLASTOMA MARKET, BY END USER, 2020–2027 (USD MILLION) 65

TABLE 41 GERMANY: GLIOBLASTOMA MARKET, BY TYPE, 2020–2027 (USD MILLION) 66

TABLE 42 GERMANY: GLIOBLASTOMA MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 66

TABLE 43 GERMANY: GLIOBLASTOMA MARKET, BY END USER, 2020–2027 (USD MILLION) 67

TABLE 44 FRANCE: GLIOBLASTOMA MARKET, BY TYPE, 2020–2027 (USD MILLION) 67

TABLE 45 FRANCE: GLIOBLASTOMA MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 67

TABLE 46 FRANCE: GLIOBLASTOMA MARKET, BY END USER, 2020–2027 (USD MILLION) 68

TABLE 47 UK: GLIOBLASTOMA MARKET, BY TYPE, 2020–2027 (USD MILLION) 68

TABLE 48 UK: GLIOBLASTOMA MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 69

TABLE 49 UK: GLIOBLASTOMA MARKET, BY END USER, 2020–2027 (USD MILLION) 69

TABLE 50 ITALY: GLIOBLASTOMA MARKET, BY TYPE, 2020–2027 (USD MILLION) 70

TABLE 51 ITALY: GLIOBLASTOMA MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 70

TABLE 52 ITALY: GLIOBLASTOMA MARKET, BY END USER, 2020–2027 (USD MILLION) 71

TABLE 53 SPAIN: GLIOBLASTOMA MARKET, BY TYPE, 2020–2027 (USD MILLION) 71

TABLE 54 SPAIN: GLIOBLASTOMA MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 71

TABLE 55 SPAIN: GLIOBLASTOMA MARKET, BY END USER, 2020–2027 (USD MILLION) 72

TABLE 56 REST OF WESTERN EUROPE: GLIOBLASTOMA MARKET, BY TYPE, 2020–2027 (USD MILLION) 72

TABLE 57 REST OF WESTERN EUROPE: GLIOBLASTOMA MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 73

TABLE 58 REST OF WESTERN EUROPE: GLIOBLASTOMA MARKET, BY END USER, 2020–2027 (USD MILLION) 73

TABLE 59 EASTERN EUROPE: GLIOBLASTOMA MARKET, BY TYPE, 2020–2027 (USD MILLION) 74

TABLE 60 EASTERN EUROPE: GLIOBLASTOMA MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 74

TABLE 61 EASTERN EUROPE: GLIOBLASTOMA MARKET, BY END USER, 2020–2027 (USD MILLION) 75

TABLE 62 ASIA-PACIFIC: GLIOBLASTOMA MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 77

TABLE 63 ASIA-PACIFIC: GLIOBLASTOMA MARKET, BY TYPE, 2020–2027 (USD MILLION) 77

TABLE 64 ASIA-PACIFIC: GLIOBLASTOMA MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 78

TABLE 65 ASIA-PACIFIC: GLIOBLASTOMA MARKET, BY END USER, 2020–2027 (USD MILLION) 78

TABLE 66 JAPAN: GLIOBLASTOMA MARKET, BY TYPE, 2020–2027 (USD MILLION) 79

TABLE 67 JAPAN: GLIOBLASTOMA MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 79

TABLE 68 JAPAN: GLIOBLASTOMA MARKET, BY END USER, 2020–2027 (USD MILLION) 80

TABLE 69 CHINA: GLIOBLASTOMA MARKET, BY TYPE, 2020–2027 (USD MILLION) 80

TABLE 70 CHINA: GLIOBLASTOMA MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 80

TABLE 71 CHINA: GLIOBLASTOMA MARKET, BY END USER, 2020–2027 (USD MILLION) 81

TABLE 72 AUSTRALIA: GLIOBLASTOMA MARKET, BY TYPE, 2020–2027 (USD MILLION) 81

TABLE 73 AUSTRALIA: GLIOBLASTOMA MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 82

TABLE 74 AUSTRALIA: GLIOBLASTOMA MARKET, BY END USER, 2020–2027 (USD MILLION) 82

TABLE 75 INDIA: GLIOBLASTOMA MARKET, BY TYPE, 2020–2027 (USD MILLION) 83

TABLE 76 INDIA: GLIOBLASTOMA MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 83

TABLE 77 INDIA: GLIOBLASTOMA MARKET, BY END USER, 2020–2027 (USD MILLION) 84

TABLE 78 SOUTH KOREA: GLIOBLASTOMA MARKET, BY TYPE, 2020–2027 (USD MILLION) 84

TABLE 79 SOUTH KOREA: GLIOBLASTOMA MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 84

TABLE 80 SOUTH KOREA: GLIOBLASTOMA MARKET, BY END USER, 2020–2027 (USD MILLION) 85

TABLE 81 REST OF ASIA-PACIFIC: GLIOBLASTOMA MARKET, BY TYPE, 2020–2027 (USD MILLION) 85

TABLE 82 REST OF ASIA-PACIFIC: GLIOBLASTOMA MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 86

TABLE 83 REST OF ASIA-PACIFIC: GLIOBLASTOMA MARKET, BY END USER, 2020–2027 (USD MILLION) 86

TABLE 84 MIDDLE EAST & AFRICA: GLIOBLASTOMA MARKET, BY REGION, 2020–2027 (USD MILLION) 88

TABLE 85 MIDDLE EAST & AFRICA: GLIOBLASTOMA MARKET, BY TYPE, 2020–2027 (USD MILLION) 88

TABLE 86 MIDDLE EAST & AFRICA: GLIOBLASTOMA MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 88

TABLE 87 MIDDLE EAST & AFRICA: GLIOBLASTOMA MARKET, BY END USER, 2020–2027 (USD MILLION) 89

TABLE 88 MIDDLE EAST: GLIOBLASTOMA MARKET, BY TYPE, 2020–2027 (USD MILLION) 89

TABLE 89 MIDDLE EAST: GLIOBLASTOMA MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 90

TABLE 90 MIDDLE EAST: GLIOBLASTOMA MARKET, BY END USER, 2020–2027 (USD MILLION) 90

TABLE 91 AFRICA: GLIOBLASTOMA MARKET, BY TYPE, 2020–2027 (USD MILLION) 91

TABLE 92 AFRICA: GLIOBLASTOMA MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 91

TABLE 93 AFRICA: GLIOBLASTOMA MARKET, BY END USER, 2020–2027 (USD MILLION) 92

TABLE 94 NEW PRODUCT LAUNCH/APPROVAL 94

TABLE 95 MERGERS & ACQUISITIONS 95

TABLE 96 PRODUCT DEVELOPMENT 96

TABLE 97 F. HOFFMANN-LA ROCHE LTD: PRODUCTS/SERVICES OFFERED 99

TABLE 98 F. HOFFMANN-LA ROCHE LTD: KEY DEVELOPMENTS 99

TABLE 99 ARBOR PHARMACEUTICALS, LLC: PRODUCTS/SERVICES OFFERED 101

TABLE 100 ARBOR PHARMACEUTICALS, LLC: KEY DEVELOPMENTS 101

TABLE 101 MERCK & CO., INC.: PRODUCTS/SERVICES OFFERED 104

TABLE 102 MERCK & CO., INC.: KEY DEVELOPMENTS 104

TABLE 103 TEVA PHARMACEUTICAL INDUSTRIES LTD: PRODUCTS/SERVICES OFFERED 107

TABLE 104 SUN PHARMACEUTICAL INDUSTRIES LTD: PRODUCTS/SERVICES OFFERED 111

TABLE 105 SUN PHARMACEUTICAL INDUSTRIES LTD: KEY DEVELOPMENTS 111

TABLE 106 AMGEN INC.: PRODUCTS/SERVICES OFFERED 114

TABLE 107 AMGEN INC.: KEY DEVELOPMENTS 114

 

14 LIST OF FIGURES

FIGURE 1 MARKET SYNOPSIS 13

FIGURE 2 MARKET ATTRACTIVENESS ANALYSIS (2020) 15

FIGURE 3 GLOBAL GLIOBLASTOMA MARKET ANALYSIS, BY TYPE 16

FIGURE 4 GLOBAL GLIOBLASTOMA MARKET ANALYSIS, BY TREATMENT 17

FIGURE 5 GLOBAL GLIOBLASTOMA MARKET ANALYSIS, BY END USER 18

FIGURE 6 GLOBAL GLIOBLASTOMA MARKET: STRUCTURE 20

FIGURE 7 BOTTOM-UP AND TOP-DOWN APPROACHES 26

FIGURE 8 MARKET DYNAMICS: ANALYSIS OF THE GLOBAL GLIOBLASTOMA MARKET 29

FIGURE 9 DRIVERS: IMPACT ANALYSIS 31

FIGURE 10 RESTRAINTS: IMPACT ANALYSIS 32

FIGURE 11 PORTER’S FIVE FORCES ANALYSIS: GLOBAL GLIOBLASTOMA MARKET 34

FIGURE 12 VALUE CHAIN ANALYSIS OF THE GLOBAL GLIOBLASTOMA MARKET 36

FIGURE 13 GLOBAL GLIOBLASTOMA MARKET SHARE, BY TYPE, 2020 (%) 40

FIGURE 14 GLOBAL GLIOBLASTOMA MARKET, BY TYPE, 2020 AND 2027 (USD MILLION) 40

FIGURE 15 GLOBAL GLIOBLASTOMA MARKET SHARE, BY TREATMENT, 2020 (%) 43

FIGURE 16 GLOBAL GLIOBLASTOMA MARKET, BY TREATMENT, 2020 AND 2027 (USD MILLION) 43

FIGURE 17 GLOBAL GLIOBLASTOMA MARKET SHARE, BY END USER, 2020 (%) 47

FIGURE 18 GLOBAL GLIOBLASTOMA MARKET, BY END USER, 2020 AND 2027 (USD MILLION) 47

FIGURE 19 GLOBAL GLIOBLASTOMA MARKET SHARE, BY REGION, 2020 (%) 50

FIGURE 20 GLOBAL GLIOBLASTOMA MARKET, BY REGION, 2020 AND 2027 (USD MILLION) 50

FIGURE 21 AMERICAS: GLIOBLASTOMA MARKET, BY REGION, 2020 AND 2027 52

FIGURE 22 NORTH AMERICA: GLIOBLASTOMA MARKET, BY COUNTRY, 2020 AND 2027 55

FIGURE 23 EUROPE: GLIOBLASTOMA MARKET, BY REGION, 2020 AND 2027 61

FIGURE 24 WESTERN EUROPE: GLIOBLASTOMA MARKET, BY COUNTRY, 2020 AND 2027 63

FIGURE 25 ASIA-PACIFIC: GLIOBLASTOMA MARKET, BY COUNTRY, 2020 AND 2027 76

FIGURE 26 MIDDLE EAST & AFRICA: GLIOBLASTOMA MARKET, BY REGION, 2020 AND 2027 87

FIGURE 27 MAJOR PLAYER MARKET SHARE ANALYSIS, 2020 (%) 93

FIGURE 28 F. HOFFMANN-LA ROCHE LTD: FINANCIAL OVERVIEW SNAPSHOT 98

FIGURE 29 F. HOFFMANN-LA ROCHE LTD: SWOT ANALYSIS 100

FIGURE 30 ARBOR PHARMACEUTICALS, LLC: SWOT ANALYSIS 102

FIGURE 31 MERCK & CO., INC.: FINANCIAL OVERVIEW SNAPSHOT 103

FIGURE 32 MERCK & CO., INC.: SWOT ANALYSIS 105

FIGURE 33 TEVA PHARMACEUTICAL INDUSTRIES LTD: FINANCIAL OVERVIEW SNAPSHOT 106

FIGURE 34 TEVA PHARMACEUTICAL INDUSTRIES LTD: SWOT ANALYSIS 107

FIGURE 35 SUN PHARMACEUTICAL INDUSTRIES LTD: FINANCIAL OVERVIEW SNAPSHOT 110

FIGURE 36 SUN PHARMACEUTICAL INDUSTRIES LTD: SWOT ANALYSIS 112

FIGURE 37 AMGEN INC.: FINANCIAL OVERVIEW SNAPSHOT 113

FIGURE 38 AMGEN INC.: SWOT ANALYSIS 115

Glioblastoma Market

The Glioblastoma Market is expected to register a CAGR of 7.60% to reach USD 2416.33 million by 2030.

$2416.33 million

Market Size


7.60%

CAGR


North America

Dominating Region

2022-2030

Forecast Period

Segmentation

By Type Primary Glioblastoma And Secondary Glioblastoma
By Treatment Surgical Procedure Radiation Therapy Chemotherapy Others
By End User Hospitals Specialty Clinics & Centers Others

Key Players

  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Arbor Pharmaceuticals LLC (US)
  • Merck & Co. Inc. (US)
  • Sun Pharmaceutical Industries Ltd (India)
  • Amgen Inc. (US)
  • and Teva Pharmaceutical Industries Ltd (Israel).

Drivers

  • Increases the healthcare expenditure
Speak to Analyst Request a Free Sample

Glioblastoma Market Overview

Glioblastoma Market is expected to register a CAGR of 7.60% to reach USD 2416.33 million by 2030. Glioblastoma is a type of brain tumor. The increasing occurrences of glioblastoma, a type of brain tumor, coupled with extensive research in glioblastoma treatment, and the rising adoption of chemotherapy are expected to fuel the growth of the glioblastoma market. However, the high cost of drugs and the failure of drug candidates in clinical trial phases are anticipated to hamper the market growth.


Market Dynamics


The increasing incidence rate of glioblastoma is expected to fuel the growth of the glioblastoma market. According to the statistics published in 2017 by the National Centre for Biotechnology Information (NCBI), glioblastoma has an incidence rate of 3.19 per 100,000 persons in the US. The growing prevalence indirectly increases the healthcare expenditure of the people as well as the government. This motivates the players operating in the market to come up with alternatives for the treatment of glioblastoma. Thus, this is likely to fuel the growth of the global glioblastoma market during the forecast period.


Glioblastoma Global Market Share, by End User, 2018 (%)  Glioblastoma Market


Source: MRFR Analysis


Segmentation


The global glioblastoma market has been segmented by type, treatment, and end user. The market, based on type, has been bifurcated into primary glioblastoma and secondary glioblastoma. Based on treatment, the glioblastoma market has been segregated into surgical procedure, radiation therapy, chemotherapy, and others. The global glioblastoma market, based on end user, has been divided into hospitals, specialty clinics and centers, and others. The specialty clinics and centers held a share of 36.8% in 2018.


Western Europe Glioblastoma Market Share, 2018 (%)  Glioblastoma Market


Source: MRFR Analysis


Regional Analysis


The glioblastoma global market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.


The Americas is likely to dominate the global glioblastoma industry. The growth in this region can be attributed to the increased cases of glioblastoma and brain tumors. Moreover, the approval of drugs helps in maximizing the growth of the market in this region.


Europe held a substantial share in the global glioblastoma market. This can be attributed to a large number of clinical trials in the region. For instance, Merck KGaA along with Vaximm GmbH is involved in Phase I and II trials to evaluate the efficacy and safety of VXM01 in combination with Avelumab in patients with resectable and non-resectable progressive glioblastoma following tumor resection and radio-chemotherapy containing temozolomide.


Asia-Pacific is estimated to be the fastest-growing region in the global market. The rise in the improved healthcare infrastructure promises a high level of research on the treatment of glioblastoma in the region.


The glioblastoma market in the Middle East & Africa is expected to witness a modest market growth rate from 2019 to 2025. The Middle East would lead the market growth in this region. Rising awareness regarding health and availability of new treatment methods are expected to drive the market growth during the assessment period.


Key Players


The prominent players in the global glioblastoma market are F. Hoffmann-La Roche Ltd (Switzerland), Arbor Pharmaceuticals, LLC (US), Merck & Co., Inc. (US), Sun Pharmaceutical Industries Ltd (India), Amgen Inc. (US), and Teva Pharmaceutical Industries Ltd (Israel).


Some of the key strategies followed by players operating in the global glioblastoma market were innovation, product development, and acquisition & mergers.



  • In May 2019, Merck entered into a definitive agreement to acquire Peloton Therapeutics, Inc., a privately held, clinical-stage biopharmaceutical company, focused on the development of novel small molecule therapeutic candidates targeting hypoxia-inducible factor-2α (HIF-2α) for the treatment of patients with cancer and other non-oncology diseases.



  • In January 2018, Amgen and Allergan PLC received the approval by the European Commission (EC) for the marketing authorization of MVASI for the treatment of glioblastoma as well as certain types of cancers.



  • In November 2016, Sun Pharma acquired Biosintez, a Russian pharmaceutical company engaged in the manufacturing and marketing of pharmaceutical products.


Market Segmentation


Glioblastoma Global Market, by Type



  • Primary Glioblastoma

  • Secondary Glioblastoma


Glioblastoma Global Market, by Treatment



  • Surgical Procedure

  • Radiation Therapy

  • Chemotherapy

  • Others


Glioblastoma Global Market, by End User



  • Hospitals

  • Specialty Clinics and Centers

  • Others


Glioblastoma Global Market, by Region



  • Americas

    • North America

      • US

      • Canada



    • Latin America





  • Europe

    • Western Europe

      • Germany

      • UK

      • France

      • Italy

      • Spain

      • Rest of Western Europe



    • Eastern Europe





  • Asia-Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific





  • Middle East & Africa

    • Middle East

    • Africa




Available Additional Customizations



  • Mega Trends in the Market

  • Glioblastoma Market: Challenges


Intended Audience



  • Pharmaceutical companies

  • Contract research manufacturing organizations

  • Research & development organizations

  • Academic institutes

Report Scope:
Report Attribute/Metric Details
  Market Size   2030: 2416.33 Mn
  CAGR   7.60%
  Base Year   2019
  Forecast Period   2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   By Type, Treatment , End User and Region
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   F. Hoffmann-La Roche Ltd (Switzerland), Arbor Pharmaceuticals, LLC (US), Merck & Co., Inc. (US), Sun Pharmaceutical Industries Ltd (India), Amgen Inc. (US), and Teva Pharmaceutical Industries Ltd (Israel)
  Key Market Opportunities

  • The high cost of drugs.
  • Failure of drug candidates in clinical trial phases.

    		•
      Key Market Drivers   Increases the healthcare expenditure


    Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    glioblastoma market is expected to reach a valuation of USD 2416.33 bmllion by 2030.

    The global market is expected to exhibit a strong 7.60% CAGR over the forecast period from 2020 to 2030.

    The growing prevalence of glioblastoma is the major driver for the global market.

    The Americas are likely to dominate the global glioblastoma market.

    Leading players in the market include F. Hoffman-La Roche, Merck, and Amgen, among others.